Contact
 
News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

Gates Foundation’s Dr. Bertozzi talks about what’s to come for HIV - February 17, 2011

Stefano Bertozzi, director of HIV and TB programs at The Gates Foundation, talks about what's to come for HIV. The RV144 HIV vaccine trial results “really reinvigorated the whole area of searching for an HIV vaccine,” he says, adding, “we hope the next trial will have greater efficacy than we did in the partial efficacy we saw in Thailand.” Read the full interview here.

Enterprise 7 Dec. 2010 Council Meeting Minutes - February 7, 2011

The Enterprise Council met via teleconference on 7 December 2010.  Minutes from the meeting are below.

Accepting Applications: Let's Talk HIV Prevention - January 31, 2011

The Global HIV Vaccine Enterprise is accepting applications for its Let’s Talk HIV Prevention series from individuals and organizations around the world interested in hosting a community event to raise awareness of the exceptional progress and challenges in HIV prevention research.  For more information, visit our web page: htt

European and Developing Countries Clinical Trial Partnership Newsletter - January 25, 2011

The European and Developing Countries Clinical Trials Partnership (EDCTP) released its January newsletter, which includes updates on governance, grant opportunities and other selected projects.  The newsletter is available below. 

Publishers cut off doctors' free access to medical journals in poor countries - January 20, 2011

The Guardian reported that wealthy publishers of the world's most important medical journals are accused of destroying an agreement with the World Health Organization to allow medics in poor countries to get online access for free. Several major publishers, including Elsevier, owner of the Lancet and Lancet Infectious Diseases, and others withdrew free access from Bangladesh at the beginning of this year. Kenya and Nigeria also have lost free access. Read the full article here.

CAPRISA 004 in Science and iPrEx in New England Journal of Medicine shortlisted for Lancet paper of the year - January 19, 2011

The CAPRISA 004 study of tenofovir gel for women published in Science in July and the iPrEx study of pre-exposure prophylaxis for men who have sex with men published in the New England Journal of Medicine in November are among 6 papers shortlisted for the Lancet paper of the year (see attached). You can have a say in whether one of them gets to the top of the pile or not.

Inovio Pharmaceuticals publishes positive preclinical results for HIV vaccine in medical journal. - January 13, 2011

Inovio Pharmaceuticals today announced the publication of a scientific paper in the medical journal Vaccine that highlights the positive preclinical trial results from the company's novel DNA vaccine targeting HIV Clade C. The vaccine candidate PENNVAX-G, is currently being tested in a 92-patient global Phase I clinical trial conducted by the U.S. Military HIV Vaccine Research Program, read the full report here.

AVAC Px Wire Release for Q1 2011 - January 12, 2011

AVAC released the first issue of Px Wire for 2011, which takes inventory of the regulatory, trial-planning and scientific agenda-setting steps that are being taken with respect to recent positive trial results. It reviews ongoing and proposed next steps that have been triggered by the Thai prime-boost AIDS vaccine trial, the CAPRISA 004 microbicide trial and the iPrEx trial of once-daily TDF/FTC for pre-exposure prophylaxis.  The report can be found here.

Major funders to share study data for public health - January 11, 2011

Seventeen major health research funding agencies from around the world, pledged to work together to support "timely and responsible" sharing of data gathered during studies on health, Reuters reported yesterday. Read the full story here.

New Enterprise-OCTAVE Workshop for Latin American Young and Early Career Investigators - December 23, 2010

The Global HIV Vaccine Enterprise and the OCTAVE Project (Online Collaborative Training for AIDS Vaccine Evaluation), in close collaboration with the Brazilian Ministry of Health (Department of STD, AIDS and Viral Hepatitis and the Oswaldo Cruz Foundation - FIOCRUZ) and the University of São Paulo- USP, is offering a new regional workshop blending online and face-to-face learning for young and early-career investigators (YECIs) from Latin America and is soliciting applications.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account